ERBB2 and breast cancer: The fourth paper was “TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients with Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer and Brain Metastases” published by Freedman RA et al., which confirmed the efficacy of neratinib plus capecitabine against refractory HER2-positive breast cancer brain metastasis (17).